A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128

Status	RECRUITING
Phase	Phase 3
Sponsor	Sanofi
Enrollment	140 participants

Key Eligibility Criteria

Inclusion (31)

- Participants are eligible to be included in the study only if all of the following criteria apply:
- Participant must have CIDP or possible CIDP criteria, based on European Academy of Neurology (EAN)/ Peripheral Nerve Society (PNS) Task Force CIDP guidelines, second revision (2021).
- Participant must have either typical CIDP, or one of the following two CIDP variants: motor CIDP (including motor predominant), multifocal CIDP (also known as Lewis Sumner Syndrome). Diagnosis must be confirmed by the adjudication committee.
- Participant must be refractory to either immunoglobulin therapy or corticosteroid therapy, as defined below.
- Immunoglobulinrefractory subgroup: Historic evidence of failure or inadequate response to immunoglobulin therapy prior to screening, defined as no clinically meaningful improvement or persistent INCAT score e2 after a minimum of:

... and 26 more (see full listing online)

Exclusion (34)

- Polyneuropathy of other causes, including but not limited to: hereditary demyelinating neuropathies, neuropathies secondary to infection or systemic disease, diabetic neuropathy, drug- or toxin-induced neuropathies, multifocal motor neuropathy, polyneuropathy related to Immunoglobulin M (IgM) monoclonal gammopathy, POEMS syndrome, and lumbosacral radiculoplexus neuropathy.
- Sensory CIDP, Distal CIDP and focal CIDP variants.
- Any other neurological or systemic disease that can cause symptoms and signs interfering with treatment or outcome assessments
- Poorly controlled diabetes (HbA1c \>7%)
- Serious infections requiring hospitalization within 30 days prior to Screening and any active infection requiring treatment during screening or presence of a condition that may predispose the participant to increased risk of infection (eg, medical history such as known immunodeficiency or history of recurrent infections)

... and 29 more (see full listing online)

Locations (122 total)

Alabama Neurology Associates- Site Number : 8400019, Homewood, Alabama, United States
USC Norris Comprehensive Cancer Center- Site Number : 8400002, Los Angeles, California, United States
University of California Irvine - Manchester Pavilion- Site Number : 8400007, Orange, California, United States
... and 119 more locations